AEON Biopharma, Inc.

AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company that entered the public markets through a SPAC combination with Priveterra Acquisition Corp, which traded on Nasdaq under the ticker PMGM and completed its initial public offering in 2021, with Priveterra Holdings LLC serving as sponsor. Operating in the healthcare and biopharma sector, AEON is focused on the development of botulinum toxin complex therapeutics. On March 3, 2022, the company filed an amended quarterly report on Form 10-Q/A with the SEC under accession number 0001104659-22-029710, providing updated financial disclosures during the pre-close period of the business combination. Sign up at SpacDesk for complete filing histories, sponsor profiles, and deal timelines on this transaction and every other active SPAC.